Dads Get Postpartum Depression, Too: Everyone Should Know Symptoms of Perinatal Mental Health Disorders; Support Is Free, Accessible and Effective
International Fathers' Mental Health Day (June 16) Brings Awareness to Seldom-Discussed Conditions; Experts Urge People to Check on Dads
PORTLAND, Ore., June 11, 2025 /PRNewswire/ -- At least one in ten fathers experience postpartum depression, although few of them realize what they are experiencing or get help. Instead, they suffer alone. Societal norms and expectations contribute to the prevalence of perinatal mental health disorders (PMHDs) and are barriers to treatment. Founded by postpartum depression survivor Mark Williams and Psychologist and PSI Advisory Board Chair Daniel Singley, Ph.D., International Fathers' Mental Health Day is held annually on the day after Father's Day (June 16 this year) to highlight key aspects of paternal mental health. Interviews are available with experts and fathers with lived experience.
Nonprofit Postpartum Support International (PSI) is working to shatter the stigma surrounding PMHDs among fathers to normalize these conditions and to encourage dads and the people who love them to know the symptoms and where to get help. Research shows:
Postpartum depression and other PMHDs, including anxiety, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar disorder, and psychosis, affect 800,000 people a year.
At least one in 10 men suffer from postpartum depression during the perinatal period, which includes pregnancy and the year following birth.
As many as 50% of fathers suffer from PMHDs when their partner is suffering.
As many as 18% of fathers develop a clinically significant anxiety disorder such as generalized anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder at some point during their partner's pregnancy or the first year postpartum.
Only 25% of those who suffer get help, and many parents are unaware that what they are experiencing is normal and treatable.
"Societal norms tell us that men are strong and should support their partners, which makes fathers feel like they are failing," Singley said. "Stigma and shame are huge reasons why so many men don't seek help, even though these conditions are common and treatable."
Men often exhibit different symptoms of depression. It can manifest itself as anger, irritation, frustration, and being short with people, or withdrawing from relationships. Dads may start drinking more alcohol or using other substances. Their loved ones and friends may not recognize the symptoms, and worse, may push struggling dads away at a time when they most need support.
"Many mental health professionals do not connect the behaviors associated with perinatal mental health disorders in men with the fact that the father may be depressed or have anxiety. We are working to change that," Singley said.
David Levine, M.D., a New Jersey pediatrician and former vice chair of PSI's Board of Directors, suffered from postpartum depression after the birth of his first son, Zachary, in 2013, and is now an advocate for dads' mental health.
"I thought Zachary hated me. Every time I was around him, he would cry. And then I started to obsessively worry he was crying constantly because there was something seriously wrong with him," Levine said. "As a pediatrician, I was keenly aware of all the potential issues. But I didn't realize I was suffering from postpartum depression."
Levine kept his feelings inside, as many fathers do. When Zachary was about six weeks old, Levine had a breakdown, which led him — with the encouragement of his wife — to start therapy. "After a few months, I could finally breathe again; I was able to be the father I wanted to be, the dad Zachary and my wife needed me to be. And now I am part of a vibrant community helping other parents who are going through what I did."
Dads and their partners should know free support is available, and no diagnosis is needed to reach out for help. PSI offers coordination, comfort, and peer support, and helps people find resources online and in their own communities. Parents can call the PSI Helpline at 1-800-944-4773 (English and Spanish), text "help" to 1-800-944-4773 (English) or 971-203-7773 (Spanish) or visit postpartum.net. The Connect by PSI app, available for download in the App Store and Google Play Store, provides free, easy access to resources.
"Adding a child to the family is stressful for all parents. There are many changes to your lifestyle, relationship, and finances, and it happens quickly; it is easy to lose your sense of self, just as you're trying to be the best parent and spouse you can," said Wendy Davis PhD, PMH-C, President and CEO of Postpartum Support International. "As part of PSI's commitment to a whole-family approach to perinatal mental health, we are proud to sponsor International Fathers' Mental Health Day to raise awareness and decrease the stigma dads often face."
PSI has an online Perinatal Mental Health Provider Directory that lists trained providers and support groups, and operates a Perinatal Psychiatric Consultation Program, through which medical providers can consult with an expert perinatal psychiatrist at no charge. PSI facilitates more than 50 free virtual support groups including those for dads, military families, LGBTQIA+ families, Spanish speakers, and more. PSI has a specialized support coordinator for dads, a volunteer who provides understanding and support for fathers who are struggling.
PSI's Chats for Dads phone meetings, held the first Tuesday of each month, provide a space where dads, partners, extended family members or other support people, and professionals can find answers and support from an expert and from each other. The sessions feature honest and compassionate talk about the adjustment to parenthood; information about how fatherhood can affect men; and helpful advice.
About Postpartum Support InternationalPostpartum Support International (PSI) was founded by a new mother in 1987 to increase awareness among public and professional communities about the emotional difficulties parents can experience during and after pregnancy. PSI offers a wealth of resources for a wide range of needs, situations, and audiences to give families the strongest and healthiest start possible through support and community. PSI also offers support, resources, best-practice training and certification for healthcare professionals and volunteer coordinators nationwide and in more than 30 countries. PSI is committed to eliminating stigma and ensuring compassionate and quality care and support are available to all families. Need help? Call 1-800-944-4PPD (4773), visit postpartum.net, or download the Connect by PSI app.
View original content to download multimedia:https://www.prnewswire.com/news-releases/dads-get-postpartum-depression-too-everyone-should-know-symptoms-of-perinatal-mental-health-disorders-support-is-free-accessible-and-effective-302478338.html
SOURCE Postpartum Support International
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®/AYVAKYT® (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. "Our presentations feature large patient populations from the PIONEER, PATHFINDER and EXPLORER trials, with follow-up reaching up to five years in ISM and up to 6.5 years in advanced SM, reflecting both the favorable long-term benefits of AYVAKIT and the unprecedented datasets we have amassed over time," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "AYVAKIT has shown transformative clinical outcomes for patients across the spectrum of SM, including sustained disease control in ISM and prolonged survival in advanced SM. These compelling results have translated into real-world practice, with clinicians expanding their view of who is an appropriate candidate for disease-modifying therapy after positive AYVAKIT experiences, and treatment durations trending toward multiple years." PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM As previously presented,1 AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3 percent) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. This data presentation follows the May 2025 online publication of PIONEER two-year efficacy and safety data in The Journal of Allergy and Clinical Immunology: In Practice. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells. Data Presentations EHA2025 Congress Oral Presentation: The Revised Mutation-Adjusted Risk Score (MARS-R) for Predicting Overall Survival in Patients with Advanced Systemic Mastocytosis Treated with Midostaurin or Avapritinib (Abstract S216) Poster Presentation: Blood-Based Proteomics for Deeper Insights Into Indolent Systemic Mastocytosis: The PIONEER Trial Experience (Abstract PS1838) Poster Presentation: High Accuracy of Peripheral Blood Testing Using Machine Learning–Derived Predictive Models to Distinguish Advanced from Indolent Systemic Mastocytosis: Analysis of Avapritinib and Elenestinib Trial Data (Abstract PF1310) Publication-Only Abstract: Phase 2/3 HARBOR Study of Elenestinib in ISM: A Trial-in-Progress Update of Novel Endpoints and Biomarkers Aimed at Evaluating Disease Modification (Abstract PB3108) EAACI Congress 2025 Flash Talk Presentation: Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study (Abstract 000621) Flash Talk Presentation: The Socio-Emotional Impact of Indolent Systemic Mastocytosis: Insights from the PRISM Survey (Abstract 000488) Poster Presentation: The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients with Indolent Systemic Mastocytosis (Abstract 001121) Data presentations are being made available in the "Science―Publications and Presentations" section of the company's website at About Systemic Mastocytosis Systemic mastocytosis (SM) is a rare disease driven by the KIT D816V mutation in about 95 percent of cases. Uncontrolled proliferation and activation of mast cells result in chronic, severe and often unpredictable symptoms across multiple organ systems. The vast majority of those affected have indolent systemic mastocytosis (ISM). A broad range of symptoms, including anaphylaxis, maculopapular rash, pruritus, diarrhea, brain fog, fatigue and bone pain, frequently persist in patients with ISM despite treatment with multiple symptom-directed therapies. This burden of disease can lead to a profound, negative impact on quality of life. Patients often live in fear of severe, unexpected symptoms, have limited ability to work or perform daily activities, and isolate themselves to protect against unpredictable triggers. Until 2023, there were no approved therapies for the treatment of ISM. A minority of patients have advanced SM, which encompasses a group of high-risk SM subtypes including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL). In addition to mast cell activation symptoms, advanced SM is associated with organ damage due to mast cell infiltration and poor survival. About AYVAKIT AYVAKIT (avapritinib) is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) to treat the root cause of SM. It was FDA approved for the treatment of advanced SM in June 2021 and ISM in May 2023. It now is indicated in adults with ISM, adults with advanced SM, including ASM, SM-AHN and MCL, and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The medicine is approved in the EU as AYVAKYT for the treatment of adults with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, adults with ASM, SM-AHN or MCL, after at least one systemic therapy, and adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. The therapy is not recommended for the treatment of patients with low platelet counts (less than 50,000/µL). Globally, the medicine is approved for one or more indications in 16 countries, including China where it is marketed by CStone Pharmaceuticals, paying tiered percentage royalties on sales. Please click here to see the full U.S. Prescribing Information for AYVAKIT, and click here to see the European Summary of Product Characteristics for AYVAKYT. Important Safety Information Intracranial Hemorrhage — Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. Overall, ICH (eg, subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In Advanced SM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts ≥50 x 109/L prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts. In ISM patients, no events of ICH occurred in the 246 patients who received any dose of AYVAKIT in the PIONEER study. Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH. Permanently discontinue AYVAKIT if ICH of any grade occurs. In Advanced SM patients, a platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in Advanced SM patients with platelet counts <50 x 109/L. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of <50 x 109/L by treatment interruption or dose reduction. Cognitive Effects — Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 33% of 995 patients overall in patients who received AYVAKIT in clinical trials including: 28% of 148 Advanced SM patients (3% were Grade ≥3), and 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC (<1% were Grade 3). Depending on the severity and indication, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue. Photosensitivity — AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment. Embryo-Fetal Toxicity — AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective method of contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks after the final dose. Adverse Reactions — The most common adverse reactions (≥20%) in patients with Advanced SM were edema, diarrhea, nausea, and fatigue/asthenia. The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing. Drug Interactions — Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided in patients with Advanced SM, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers. If contraception requires estrogen, limit ethinyl estradiol to ≤20 mcg unless a higher dose is necessary. To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or AYVAKIT is available in 25-mg, 50-mg, 100-mg and 200-mg tablets. Please click here to see the full U.S. Prescribing Information for AYVAKIT. About Blueprint Medicines Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with SM in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases and solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Blueprint Medicines' leadership role and its ability to transform treatment across the spectrum of SM, including sustained disease control in ISM and prolonged survival in advanced SM; AYVAKIT/AYVAKYT's position as the durable standard of care and clinicians' view of appropriate candidates and treatment duration; plans and expectations for Blueprint Medicines' current or future approved drugs and drug candidates; the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; and Blueprint Medicines' strategy, goals, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to Blueprint Medicines' ability and plans in continuing to build out and expand a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT/AYVAKYT or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT or any drug candidates it is developing; Blueprint Medicines' ability to successfully expand its operations, research platform and portfolio of therapeutic candidates, and the timing and costs thereof; the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing arrangements; and the ability of the parties to consummate the proposed merger between Blueprint Medicines and Sanofi on the timeline anticipated or at all, including the occurrence of any event, change or other circumstance that could give rise to the termination of the merger. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements. Footnote 1 Reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress Trademarks Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation. View original content to download multimedia: SOURCE Blueprint Medicines Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Cancer Pain Market Set to Transform by 2034 Due to Launch of Breakthrough Therapies
According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more drug development. The market is expected to show positive growth, mainly attributed to the increasing cases and also, the launch of upcoming therapies during the forecast period. LAS VEGAS, June 12, 2025 /PRNewswire/ -- DelveInsight's Cancer Pain Market Insights report includes a comprehensive understanding of current treatment practices, cancer pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Cancer Pain Market Report According to DelveInsight's analysis, the market size for cancer pain is expected to rise at a significant CAGR by 2034. The United States is expected to account for the highest market size of cancer pain, of the total market size in 7MM in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight's analysis, the total cancer pain cases in 2023 for the US were 2.4 million. In 2023, based on the pathophysiology of cancer pain, nociceptive pain accounted for the highest number of cases in the US. Leading cancer pain companies developing emerging therapies, such as InhaleRX, Dogwood Therapeutics, WinSanTor, AlgoTherapeutix, Artelo Biosciences, Asahi Kasei Pharma, and others, are developing novel cancer pain drugs that can be available in the cancer pain market in the coming years. The promising cancer pain therapies in the pipeline include IRX211, HALNEURON (tetrodotoxin), WST-057, ATX01, ART26.12, ART-123, and others. Discover which therapies are expected to grab the major cancer pain market share @ Cancer Pain Market Report Cancer Pain Overview Cancer pain is a common and often debilitating symptom experienced by individuals with cancer, resulting from a variety of causes such as tumor invasion into surrounding tissues, inflammation, nerve compression, or the side effects of treatments like chemotherapy, radiation, and surgery. The nature of cancer pain can vary significantly, it may be acute or chronic, localized or widespread, and described as dull, sharp, burning, or throbbing. Pain not only affects a patient's physical functioning but also takes a toll on emotional well-being, often leading to anxiety, depression, and sleep disturbances. Effective pain management is crucial to maintaining quality of life and supporting overall treatment goals. Cancer Pain Epidemiology Segmentation The cancer pain epidemiology section provides insights into the historical and current cancer pain patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The cancer pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Cases of Cancer Pain Etiology-specific Cases of Cancer Pain Incident Cases of Chemotherapy-Induced Peripheral Neuropathy Severity-specific Cases of Cancer Pain Pathophysiology-specific Cases of Cancer Pain Temporal Variation-specific Cases of Cancer Pain Incident Cases of Breakthrough Cancer Pain (BTcP) Cancer Pain Treatment Market Managing chronic cancer-related pain should be personalized, balancing the benefits and drawbacks within the broader context of the patient's overall care goals. When planning pain management, it's important to consider whether disease-modifying treatments are feasible, appropriate, and how they might impact pain. If the pain is localized and caused by tumor pressure or destruction, such as bone lesions, radiotherapy can be very effective. Regardless of whether primary treatments are possible, many patients with active disease-related pain will still require symptom-focused therapies. A thorough pain evaluation is essential to develop a comprehensive, multimodal treatment plan. The first step is to set realistic expectations for the patient, since the cause of the pain affects the likely improvement in pain levels and daily functioning. Patients can be offered various treatment options, including over-the-counter pain relievers, non-opioid prescriptions, procedural interventions, complementary therapies, and systemic opioids. For moderate to severe cancer pain, opioids remain the cornerstone of treatment. Long-term opioid use aims to achieve consistent, meaningful pain relief with manageable side effects, ultimately improving quality of life. Pure μ-opioid receptor agonists are generally preferred for cancer pain, except for drugs like pethidine and dextropropoxyphene, which are discouraged due to their risk of adverse effects. While partial agonists like buprenorphine and mixed-mechanism drugs such as tramadol and tapentadol are options, pure μ-agonists are more commonly used and allow for more flexible dosing. Patients have access to various non-opioid treatment options, which include both medication-based and non-medication approaches. Acetaminophen is often used as a first-choice therapy for patients experiencing mild cancer pain who either do not need opioids or prefer to avoid them. It can also be combined with opioids, and some prescribed medications include both acetaminophen and an opioid in a single tablet for convenience. However, its use in cancer patients is limited due to the risk of liver toxicity, especially in those with liver conditions, and requires careful monitoring for fever in patients with neutropenia. To know more about cancer pain treatment guidelines, visit @ Cancer Pain Management Cancer Pain Pipeline Therapies and Key Companies IRX211: InhaleRX HALNEURON (tetrodotoxin): Dogwood Therapeutics WST-057: WinSanTor ATX01: AlgoTherapeutix ART26.12: Artelo Biosciences ART-123: Asahi Kasei Pharma Discover more about cancer pain drugs in development @ Cancer Pain Clinical Trials Cancer Pain Market Dynamics The cancer pain market dynamics are expected to change in the coming years. The increasing global prevalence of cancer and rising awareness of cancer-associated pain are expected to drive growth in the cancer pain therapeutics market. With no recent drug approvals in this space, pharmaceutical companies have a significant opportunity to penetrate the market, particularly by developing nonopioid-based treatments. As opioids continue to dominate cancer pain management, the anticipated launch of drugs like tetrodotoxin signals a major shift toward novel, nonopioid mechanisms, highlighting the vast potential for innovation in this therapeutic area. Furthermore, potential therapies are being investigated for the treatment of cancer pain, and it is safe to predict that the treatment space will significantly impact the cancer pain market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the cancer pain market in the 7MM. However, several factors may impede the growth of the cancer pain market. Poor assessment of pain, inadequate clinician knowledge, lack of coverage and uneven healthcare reimbursement policies, and the limited effectiveness of standard pain medications such as opioids in cases of refractory pain have all been identified as major barriers to effective cancer pain management, underscoring the need to improve understanding of pain and leverage that knowledge to develop new and more effective treatments. Moreover, cancer pain treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the cancer pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the cancer pain market growth. Cancer Pain Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Cancer Pain Companies InhaleRX, Dogwood Therapeutics, WinSanTor, AlgoTherapeutix, Artelo Biosciences, Asahi Kasei Pharma, and others Key Pipeline Cancer Pain Therapies IRX211, HALNEURON (tetrodotoxin), WST-057, ATX01, ART26.12, ART-123, and others Scope of the Cancer Pain Market Report Therapeutic Assessment: Cancer Pain current marketed and emerging therapies Cancer Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Cancer Pain Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cancer Pain Market Access and Reimbursement Download the report to understand which factors are driving cancer pain market trends @ Cancer Pain Market Trends Table of Contents 1. Cancer Pain Market Key Insights 2. Cancer Pain Market Report Introduction 3. Cancer Pain Market Overview at a Glance 4. Cancer Pain Market Executive Summary 5. Disease Background and Overview 6. Cancer Pain Treatment and Management 7. Cancer Pain Epidemiology and Patient Population 8. Patient Journey 9. Cancer Pain Marketed Drugs 10. Cancer Pain Emerging Drugs 11. Seven Major Cancer Pain Market Analysis 12. Cancer Pain Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Related Reports Cancer Pain Epidemiology Forecast Cancer Pain Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the cancer pain epidemiology trends. Advanced Cancer Pain Management Pipeline Advanced Cancer Pain Management Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced cancer pain management companies, including Tetra Bio-Pharma, ZYUS Life Sciences, among others. Advanced Cancer Pain Management Market Advanced Cancer Pain Management Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced cancer pain management companies, including Tetra Bio-Pharma, ZYUS Life Sciences, among others. Cancer Supportive Care Drugs Market Cancer Supportive Care Drugs Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key cancer supportive care drugs companies, including Helsinn Healthcare SA, Merck & Co., Inc., Sanofi, Pfizer Inc., GSK plc, F. Hoffmann-La Roche Ltd., Amgen Inc., Novartis AG, Viatris Inc., Nimbus Therapeutics, Gilead Sciences, Inc., Eli Lilly and Company, Moderna, Inc., AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Otsuka Holdings Co., Ltd., Affimed GmbH, Bristol-Myers Squibb Company, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ + Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
StopTheBleed.com Launches As A Dedicated Resource for Bleeding Control Kits
LELAND, N.C., June 12, 2025 /PRNewswire/ -- In recognition of the 10th anniversary of the STOP THE BLEED® initiative, Rescue Essentials is proud to announce the launch of a streamlined e-commerce destination for officially licensed STOP THE BLEED® kits and mass casualty response solutions. Designed to help organizations of all sizes prepare for bleeding emergencies, provides expertly curated kits for schools, public buildings, factories, offices, and anywhere else traumatic bleeding can happen. Each kit is built at our North Carolina facility with trusted components from Rescue Essentials and other leading manufacturers such as SAM Medical and North American Rescue " makes it easier than ever for people to find the exact bleeding control kits they need, whether to comply with local legislation or simply to be better prepared," said Jim Seidel, Rescue Essentials CEO. "Our team is here to assist with product selection, identify applicable state requirements, and even help customers locate available grant funding to support their preparedness goals." As a licensed partner of the U.S. Department of Defense's STOP THE BLEED® program, Rescue Essentials is committed to supporting this international public health initiative, which empowers bystanders to take action and save lives in the critical moments following a traumatic injury. represents Rescue Essentials' continued dedication to delivering high-quality, accessible medical response products and training support to first responders, safety officials and everyday heroes across the country. About Rescue Essentials Since 2007, Rescue Essentials has remained focused on its original goal — to offer top quality tactical, emergency, combat, and outdoor medical products at affordable prices, delivered in a timely manner. Rescue Essentials' core capabilities include the design, manufacture, and assembly of purpose-built trauma and medical kits for law enforcement, EMS and government agencies. Rescue Essentials, a division of Tri-Tech Forensics, Inc., is based in Leland, N.C. View original content to download multimedia: SOURCE Tri-Tech Forensics
